Comparative bioavailability of two moxifloxacin tablet products after single dose administration under fasting conditions in a balanced, randomized and cross-over study in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 3, 2013, Pages 249-254

  Kanjanawart, Sirimas ^a   Gaysonsiri, Dhanu ^a   Phunikom, Katcharin ^a   Simasathiansopon, Sontaya ^a   Tangsucharit, Panot ^a   Vannaprasaht, Suda ^a   Kaewkamson, Thanawat ^a   Tassaneeyakul, Wichittra ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Bioequivalence; Moxifloxacin; Pharmacokinetic parameters

Indexed keywords

GENERIC DRUG; MOXIFLOXACIN; RAPIFLOX; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; FILM COATED TABLET; FILM COATING; GASTROINTESTINAL SYMPTOM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET; THAILAND; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FASTING; FEMALE; HUMANS; MALE; QUINOLINES; TABLETS;

EID: 84874686906     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201748     Document Type: Article

References (9)

1. Balfour JA, Wiseman LR. Moxifloxacin. Drugs. 1999; 57: 363-373. doi:10.2165/00003495-199957030-00007 PubMed
2. Ballow C, Lettieri J, Agarwal V, Liu P, Stass H, Sullivan JT. Absolute bioavailability of moxifloxacin. Clin Ther. 1999; 21: 513-522. doi:10.1016/S0149-2918(00)88306-X PubMed
3. Keating GM. Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis. Drugs. 2011; 71: 89-99. doi:10.2165/11205840-000000000-00000 PubMed
4. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother. 2000; 44: 2600-2603. doi:10.1128/AAC.44.10.2600-2603.2000 PubMed
5. Metallidis S, Charokopos N, Nikolaidis J, Alexiadou E, Lazaraki G, Koumentaki E, Tsona A, Theodoridis G, Nikolaidis P. Penetration of moxifloxacin into sternal bone of patients undergoing routine cardiopulmonary bypass surgery. Int J Antimicrob Agents. 2006; 28: 428-432. doi:10.1016/j.ijantimicag.2006.08. 019 PubMed
6. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 (Suppl B): 83-90.
7. Stass H, Rink AD, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother. 2006; 58: 693-696. doi:10.1093/jac/dkl305 PubMed
8. Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, Leese PT, Watson S, Heller AH. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother. 1999; 43: 2793-2797. PubMed
9. Yoshida K, Okimoto N, Kishimoto M, Fukano H, Hara H, Yoneyama H, Moriya O, Kawanishi M, Kimura M, Matsushima T, Niki Y. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. J Infect Chemother. 2011; 17: 678-685. doi:10.1007/s10156-011-0282-6 PubMed